Iheezo, a topical anesthetic approved by the FDA in Sept. 2022, is the first ocular anesthetic approved for use in 14 years, according to a Feb. 2 press release.
Iheezo does not require patients to receive any supplemental anesthesia to undergo surgical procedures.
By receiving a product-specific CMS code, ophthalmologists, optometrists and retina specialists will be able to easily bill for Iheezo, creating greater accessibility for the product.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
